Literature DB >> 6777461

Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.

S Franceschetti, G Uziel, S Di Donato, L Caimi, G Avanzini.   

Abstract

A 22 year old patient with non-familial progressive myoclonus, macular cherry-red spot, moderate cerebellar syndrome and normal intelligence is described. The myoclonus began at the age of 18 years. Focal myoclonus could easily be elicited by voluntary and passive movements, and by touch and electrical stimulation of median nerve. Somatosensory evoked potentials showed a high voltage early component. Jerk-locked averaging of the EEG preceding action myoclonus detected an otherwise hidden, time-related, EEG spike. The myoclonus responded partially but clearly to L-5 hydroxytryptophan plus carbidopa treatment. Biochemical study showed an alpha-neuraminidase deficiency in cultured fibroblasts: the decrease in this enzyme activity was compared to that found in a patient affected by mucolipidosis III.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6777461      PMCID: PMC490715          DOI: 10.1136/jnnp.43.10.934

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes.

Authors:  S Hickman; E F Neufeld
Journal:  Biochem Biophys Res Commun       Date:  1972-11-15       Impact factor: 3.575

2.  Studies on the pathogenetic mechanism of I-cell disease in cultured fibroblasts.

Authors:  U N Wiesmann; N N Herschkowitz
Journal:  Pediatr Res       Date:  1974-11       Impact factor: 3.756

3.  A new type of mucolipidosis with -galactosidase deficiency and glycopeptiduria.

Authors:  T Orii; R Minami; K Sukegawa; S Sato; S Tsugawa
Journal:  Tohoku J Exp Med       Date:  1972-08       Impact factor: 1.848

4.  [Pharmacological analysis of a case of postanoxic intention and action myoclonus].

Authors:  F Lhermitte; M Peterfalvi; R Marteau; J Gazengel; M Serdaru
Journal:  Rev Neurol (Paris)       Date:  1971-01       Impact factor: 2.607

5.  Mucolipidosis I: increased sialic acid content and deficiency of an alpha-N-acetylneuraminidase in cultured fibroblasts.

Authors:  M Cantz; J Gehler; J Spranger
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

6.  Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.

Authors:  M H Van Woert; D Rosenbaum; J Howieson; M B Bowers
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

7.  Macular cherry-red spots and beta-galactosidase deficiency in an adult. An autopsy case with progressive cerebellar ataxia, myoclonus, thrombocytopathy, and accumulation of polysaccharide in liver.

Authors:  Y Suzuki; N Nakamura; Y Shimada; H Yotsumoto; H Endo; K Nagashima
Journal:  Arch Neurol       Date:  1977-03

8.  Deficit in neuraminidase associated with mucolipidosis II (I-cell disease).

Authors:  G Strecker; J C Michalski; J Montreuil; J P Farriaux
Journal:  Biomedicine       Date:  1976-09-30

9.  Localized beta-galactosidase deficiency. Occurrence in cerebellar ataxia with myoclonus epilepsy and macular cherry-red spot--a new variant of GM1-gangliosidosis?

Authors:  A Yamamoto; S Adachi; S Kawamura; M Takahashi; T Kitani
Journal:  Arch Intern Med       Date:  1974-10

10.  Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblasts.

Authors:  G H Thomas; G E Tiller; L W Reynolds; C S Miller; J W Bace
Journal:  Biochem Biophys Res Commun       Date:  1976-07-12       Impact factor: 3.575

View more
  2 in total

Review 1.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

Review 2.  Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.

Authors:  Aiza Khan; Consolato Sergi
Journal:  Diagnostics (Basel)       Date:  2018-04-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.